Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for the ...

TauRx Pharma's effort to bring a tau-targeting drug for Alzheimer's disease (AD) to market has been a marathon, with a number of setbacks over the years, but the company reckons it may finally be ...

An interactive toolbox for standardizing, validating, simulating, reducing, and exploring detailed biophysical models that can be used to reveal how morpho-electric properties map to dendritic and ...